NCT00052169 - Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

September 30, 2006

Conditions

Breast Neoplasms

Interventions

DRUG

ZD1839 in combination with docetaxel

Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.

Trial Locations (1)

15212

NSABP Operations Center, Pittsburgh